BioMarin lands three-year deal for German coverage of gene therapy at $900K per patient

Bio­Marin an­nounced a new three-year deal on Tues­day with the Ger­man Na­tion­al As­so­ci­a­tion of Statu­to­ry Health In­sur­ance Funds (GKV-SV), which cov­ers about 90% of the Ger­man pop­u­la­tion, for re­im­burse­ment of its gene ther­a­py Roc­ta­vian (val­oc­toco­gene rox­a­parvovec-rvox) for pa­tients with se­vere he­mo­phil­ia A.

The Cal­i­for­nia-based com­pa­ny said its one-time, sin­gle-dose ther­a­py de­liv­ered via in­tra­venous in­fu­sion over three to four hours will have a gross price of €28,933.53 (about $31,780) per vial in Ger­many. That trans­lates to about $900,000 in net rev­enue per pa­tient for Bio­Marin at the cur­rent ex­change rate, the com­pa­ny said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.